Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).
Epistemonikos ID: dddfb8646d153ee7eb7f0f33be80172647dbcbd8
First added on: Oct 30, 2026